Literature DB >> 25971283

Intra-abdominal pressure, Cardiac Index and vascular resistance during hyperthermic intraperitoneal chemotherapy: a prospective observational study.

Christoph N Schluermann1, Jens Hoeppner, Christoph Benk, Rene Schmidt, Torsten Loop, Johannes Kalbhenn.   

Abstract

BACKGROUND: Increased intra-abdominal pressure and hemodynamic variations during hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be comparable to pneumoperitoneum with decreased Cardiac Index (CI) and increased Systemic Vascular Resistance Index (SVRI). We hypothesized that despite comparable increased intra-abdominal pressure, hemodynamic changes during HIPEC would substantially differ from those described in laparoscopic surgery.
METHODS: In this prospective observational clinical study, after obtaining written informed consent, we assessed intra-abdominal pressure and hemodynamic and respiratory changes during HIPEC in 10 consecutive patients. Intra-abdominal pressure as the primary endpoint was continuously measured with a catheter placed in the abdominal cavity. Secondary endpoints were hemodynamic changes measured by pulse contour analysis and respiratory alterations. Fluid management was based on stroke volume variation.
RESULTS: The mean intra-abdominal pressure was constantly elevated during HIPEC at a level of 14.2 mmHg (P=0.002 compared to baseline). The mean SVRI dropped from 1716 dyn*sec/cm³/m² to 1490 dyn*sec/cm⁵/m² at the end of HIPEC (P<0.05). Mean CI increased from 3.2 to 3.45 L/m² (P<0.001) and Horovitz index decreased from 548 to 380 (P=0.001). Median fluid intake was 7000 mL. No patient developed acute kidney injury.
CONCLUSIONS: Increased intra-abdominal pressure during HIPEC was comparable to pneumoperitoneum. Hemodynamic changes however were opposed with a decrease in SVRI and a compensative increase in CI. Current guidelines for anesthetic management in patients undergoing HIPEC are mainly based on findings from laparoscopic surgery and should therefore be reconsidered critically.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25971283

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  5 in total

1.  Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  June S Peng; Jessica LaPiano; Katy Wang; Kristopher Attwood; Joseph J Skitzki; John M Kane; Valerie A Francescutti
Journal:  Ann Surg Oncol       Date:  2021-08-12       Impact factor: 5.344

2.  Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study.

Authors:  Cristina Rodríguez Silva; Francisco Javier Moreno Ruiz; Inmaculada Bellido Estévez; Joaquin Carrasco Campos; Alberto Titos García; Manuel Ruiz López; Ivan González Poveda; Jose Antonio Toval Mata; Santiago Mera Velasco; Julio Santoyo Santoyo
Journal:  World J Surg Oncol       Date:  2017-02-21       Impact factor: 2.754

3.  Physiologic and hemodynamic changes in patients undergoing open abdominal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Myoung Hwa Kim; Young Chul Yoo; Sun Joon Bai; Kang-Young Lee; Nayeon Kim; Ki Young Lee
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

4.  Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer with Incidental Bochdalek Hernia and Postoperative Bilateral Thalamic Infarct: A Case Report.

Authors:  Ilker Kahramanoglu; Hasan Turan; Ece Yamak Altinpulluk; Zahid Mammadov; Tugan Bese; Macit Arvas; Fuat Demirkiran
Journal:  Case Rep Oncol       Date:  2017-03-28

5.  Changes in Hepatic Blood Flow and Liver Function during Closed Abdominal Hyperthermic Intraperitoneal Chemotherapy following Cytoreduction Surgery.

Authors:  Stéphanie Dupont; Eduardo R C Schiffer; Marion J White; John R A Diaper; Marc-Joseph Licker; Philippe C Masouyé
Journal:  Gastroenterol Res Pract       Date:  2018-03-12       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.